State-of-the-Art Equipment for Preclinical Molecular Imaging and Targeted Radiotherapy

点击翻译按钮获取中文摘要

Numerous chronic diseases, such as cancer and early heart disease, are often symptomless. Consequently, these diseases are often diagnosed at a late stage which reduces the treatment options that are available to the patient. We are creating new ways of seeing inside the body to identify the processes that go wrong with these devastating diseases using a process called 'molecular imaging'. These innovative scans require the administration of radioactive drugs into the blood stream. The drugs home to the site of the disease, or identify a particular feature related to the disease that will help medical professionals provide the correct treatments for the specific patient. The radioactivity is needed so advanced medical scanners can identify the disease location in the body. Instead of taking a picture of the outside, these scanners can see deep within the body and locate regions of disease that are just millimetres in size. The type and amount of radioactivity used are not harmful but provide the 'beacon' so these diseases can visualised by the scanner.At King's College London we have pioneered the discovery of new molecular imaging applications for the past fifteen+ years. We have built a critical mass and extensive research infrastructure to make pioneering discoveries in molecular imaging research with the ultimate goal of improving human health. This exciting area of research is now on the cusp of new discoveries to not only see but treat disease. By changing the nature of the radioactivity attached to the drug we can deliver a targeted therapeutic payload to the site of disease, resulting in its elimination. Known as 'radionuclides therapies', they have already shown improvements over normal chemotherapy in prostate cancer patients with a lower number of side effects. At King's College London we have the facilities, know-how and ambition to make a significant contribution to this emerging field of research.To fully exploit our critical mass in molecular imaging and radionuclide research we require new scanners to detect both imaging and therapeutic radioactivity. Here, we have requested funds to purchase miniaturised clinical scanners for research using animal models of human diseases. Replacing our >12-year-old equipment they possess advanced features that enable researchers to develop and optimise these imaging tools before their use in humans. Specifically, we will be able to track the movement of these radioactivity-based treatments throughout the body in real time. The improved resolution of the scans will also allow us to identify microstructures in the body or track just a few thousand therapeutic cells that are injected to fight cancer. Working with researchers across the UK will use these scanners to improve our understanding of a host of different diseases including cancer, neurodegenerative disorders, heart disease, pregnancy, inflammatory disorders, and arthritis. Finally, by partnering with pharmaceutical and biotech companies we aim to commercialise these discoveries to deliver maximum benefit to a wide range of patients both in the UK and world-wide.